OTLK
Outlook Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.46
−0.57%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.46
From 52W high−81.48%
Volume1.38M
Market cap$111.35M
P/E (TTM)—
P/S (TTM)−95.7x
Div yield—
Key dataNov 4, 2026
Open
$0.46
From 52W high
−81.48%
Volume
1.38M
Market cap
$111.35M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.9x
P/E (TTM)
—
RSI (14)
36.4
MomentumView details →
1D Return
−0.57%
YTD Return
−70.25%
SummaryUpdated Jun 1, 2026
Outlook Therapeutics, Inc. (NASDAQ:OTLK) is a late-stage biopharmaceutical company founded in 2010 and headquartered in Iselin, New Jersey. Originally incorporated as Oncobiologics, Inc., the company rebranded to Outlook Therapeutics in November 2018 to reflect its strategic pivot toward ophthalmology. The company went public in 2016 and has evolved from a broader oncology focus to specialize exclusively in developing monoclonal antibody treatments for eye diseases, particularly retinal disorders that can cause blindness.
Similar companies
Latest newsMore news →
Outlook Therapeutics, Inc. named Greg DiPasquale chief commercial officer to lead U.S. commercialization of LYTENAVA.26d agoOutlook Therapeutics, Inc. received a NASDAQ notice dated September 25, 2026 that it no longer complies with the minimum bid price requirement under Rule 5550(a)(2), with a compliance deadline of March 24, 2027.35d ago